Vol 70, No 4 (2019)
Review paper
Published online: 2019-08-14

open access

Page views 2039
Article views/downloads 1705
Get Citation

Connect on Social Media

Connect on Social Media

Current surgical management in RET mutation carriers [Aktualne postępowanie chirurgiczne u nosicieli mutacji proto-onkogenu RET]

Agnieszka Czarniecka1, Małgorzata Oczko-Wojciechowska2, Anna Hajduk2, Marcin Zeman1, Barbara Jarzab2
Pubmed: 31489961
Endokrynol Pol 2019;70(4):367-379.


Medullary thyroid carcinoma (MTC) still remains a rare endocrine tumor. 20-25% of MTC cases are genetically determined. The detection of the RET proto-oncogene mutation in 1993 allowed to understand the unique genotype-phenotype relationships in hereditary medullary thyroid carcinoma (HMTC) and formed the basis for therapeutic decisions based on the molecular results. Currently, prophylactic thyroidectomy is a commonly adopted and accepted therapeutic method. The decision on the time and extent of surgery should be made based on the results of molecular examination, the assessment of calcitonin (Ct) concentration and family history. Treatment of patients with HMTC requires the cooperation of a multidisciplinary team of experts and should be done in specialized centers only. The study is a review of the current guidelines for surgical management in the MEN2 syndrome.

Article available in PDF format

View PDF Download PDF file


  1. Schlumberger M, Pacini F, Tuttle R. Medullary thyroid carcinoma. Thyroid Tumors Estimprim, Besançon, France 2016: 357–361.
  2. Wells SA. Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors. Endocr Relat Cancer. 2018; 25(2): T1–T13.
  3. Elisei R, Pinchera A. Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol. 2012; 8(8): 466–475.
  4. Shepet K, Alhefdhi A, Lai N, et al. Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival. Ann Surg Oncol. 2013; 20(5): 1451–1455.
  5. Delbridge L, Robinson B. Genetic and biochemical screening for endocrine disease: III. Costs and logistics. World J Surg. 1998; 22(12): 1212–1217.
  6. Goretzki PE, Höppner W, Dotzenrath C, et al. Genetic and biochemical screening for endocrine disease. World J Surg. 1998; 22(12): 1202–1207.
  7. Lifante JC, Blanchard C, Mirallié E, et al. Role of preoperative basal calcitonin levels in the timing of prophylactic thyroidectomy in patients with germline RET mutations. World J Surg. 2014; 38(3): 576–581.
  8. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993; 2(7): 851–856.
  9. Mulligan LM, Kwok JB, Healey CS. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993; 363(6428): 458–460.
  10. Machens A, Ukkat J, Brauckhoff M, et al. Advances in the management of hereditary medullary thyroid cancer. J Intern Med. 2005; 257(1): 50–59.
  11. Wells SA, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg. 1994; 220(3): 237–47; discussion 247.
  12. Wloch J, Oczko-Wojciechowska M, Szpak-Ulczok S, et al. [Medullary thyroid carcinoma: from molecular studies to clinical decisions]. Endokrynol Pol. 2005; 86(3): 362–369.
  13. Machens A, Dralle H, Lorenz K. Prophylactic thyroidectomy in RET carriers at risk for hereditary medullary thyroid cancer. Thyroid. 2009; 19(6): 551–554.
  14. Zhang X, Yan D, Wang J, et al. Is new American Thyroid Association risk classification for hereditary medullary thyroid carcinoma applicable to Chinese patients? A single-center study. Chin J Cancer Res. 2017; 29(3): 223–230.
  15. Wang TS, Opoku-Boateng A, Roman SA, et al. Prophylactic thyroidectomy: who needs it, when, and why. J Surg Oncol. 2015; 111(1): 61–65.
  16. Kluijfhout WP, van Beek DJ, Verrijn Stuart AA, et al. Postoperative Complications After Prophylactic Thyroidectomy for Very Young Patients With Multiple Endocrine Neoplasia Type 2: Retrospective Cohort Analysis. Medicine (Baltimore). 2015; 94(29): e1108.
  17. Plaza-Menacho I. Structure and function of RET in multiple endocrine neoplasia type 2. Endocr Relat Cancer. 2018; 25(2): T79–T90.
  18. Zhang M, Liu Y, Fu J, et al. Functional analysis of RET with multiple endocrine neoplasia type 2. J Cancer Res Ther. 2017; 13(5): 823–828.
  19. Wells SA, Asa SL, Dralle H, et al. American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015; 25(6): 567–610.
  20. Jarząb B, Dedecjus M, Słowińska-Klencka D, et al. Diagnostics and Treatment of Thyroid Carcinoma. Endokrynol Pol. 2016; 67(1): 74–107.
  21. Grey J, Winter K. Patient quality of life and prognosis in multiple endocrine neoplasia type 2. Endocr Relat Cancer. 2018; 25(2): T69–T77.
  22. Jarzab B, Szpak-Ulczok S, Wloch J, et al. Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers — the role of Ct serum level. Thyroid Res. 2013; 6 Suppl 1: S9.
  23. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf). 1998; 48(3): 265–273.
  24. Starenki D, Park JI. Pediatric Medullary Thyroid Carcinoma. J Pediatr Oncol. 2015; 3(2): 29–37.
  25. Czarniecka A. Dwadzieścia lat doświadczeń z operacjami profilaktycznymi w dziedzicznym raku rdzeniastym tarczycy. Endokrynol Pol. 2018; 69(Suppl A): A5.
  26. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001; 86(12): 5658–5671.
  27. Kloos RT, Eng C, Evans DB, et al. American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009; 19(6): 565–612.
  28. Jarząb B, Król A, Hasse-Lazar K, et al. Presentation of points of general discussion and voting among the speakers of the European Thyroid Association-Cancer Research Network (ETA-CRN) meeting in Lisbon, 2009, entitled "European comments to ATA medullary thyroid cancer guidelines". Thyroid Res. 2013; 6 (Suppl 1): S11.
  29. Rohmer V, Vidal-Trecan G, Bourdelot A, et al. Groupe Français des Tumeurs Endocrines. Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2011; 96(3): E509–E518.
  30. Elisei R, Romei C, Renzini G, et al. The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab. 2012; 97(2): 426–435.
  31. Romei C, Mariotti S, Fugazzola L, et al. ItaMEN network. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol. 2010; 163(2): 301–308.
  32. Pappa T, Alevizaki M. Management of hereditary medullary thyroid carcinoma. Endocrine. 2016; 53(1): 7–17.
  33. Kowalska A. Rak rdzeniasty tarczycy — możliwości leczenia systemowego. Endokrynol Pol. 2018; 69(Suppl A): A12.
  34. Schlumberger M, Bastholt L, Dralle H, et al. European Thyroid Association Task Force. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012; 1(1): 5–14.
  35. Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med. 2005; 257(1): 27–37.
  36. Raue F, Kraimps JL, Dralle H, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med. 1995; 238(4): 369–373.